MGC (ASX:MXC) will conduct a head-to-head clinical study on severe intractable epilepsy in collaboration with Cannabis Access Clinics and Epilepsy Action Australia, a direct comparison assessing the efficacy of low-THC to 100 per cent CBD products when treating severe intractable epilepsy.
Read more :
Applied Cannabis Research welcomes PM Scott Morrison’s announcement of a Royal Commission into suicide among Australia’s veterans and serving Defence personnel. We
Aruma Labs teams up with Applied Cannabis Research for endometriosis observational study Applied Cannabis Research is pleased to announce Aruma Labs (Aruma)
The CMOS is expected to run for five years, with patients to be recruited nationwide via medical centers, prescribing GP’s, and specialists.
© 2021 All rights reserved, Applied Cannabis Research
